{
  "title": "Retatrutide vs tirzepatide",
  "page": "https://stemcellatlas.com/en/compare/retatrutide-vs-tirzepatide",
  "snapshot_date": "2026-08-30",
  "headers": [
    "Question",
    "Tirzepatide / Zepbound",
    "Retatrutide"
  ],
  "rows": [
    [
      "Receptor targets",
      "GIP + GLP-1",
      "GIP + GLP-1 + glucagon"
    ],
    [
      "Source for US product status",
      "Current Zepbound prescribing information",
      "FDA unapproved-GLP-1 notice"
    ],
    [
      "Approved product in this comparison",
      "Zepbound injection",
      "None identified by the cited FDA notice"
    ],
    [
      "Research record to open",
      "Clinical studies in the label",
      "TRIUMPH-1: NCT05929066"
    ],
    [
      "What the source establishes",
      "Specific labelled uses and safety information",
      "A trial programme, not a retail medicine approval"
    ]
  ],
  "scope": "Editorially selected comparison, not an exhaustive review or clinical recommendation.",
  "sources": [
    "https://clinicaltrials.gov/study/NCT05929066",
    "https://investor.lilly.com/node/54321/pdf",
    "https://pi.lilly.com/us/zepbound-uspi.pdf",
    "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss"
  ],
  "registry_records": [
    {
      "registry": "ClinicalTrials.gov",
      "nct_id": "NCT05929066",
      "registry_last_update_posted": "2026-08-21",
      "retrieved_on": "2026-08-30",
      "modifications": "Selected fields, shortened labels and editorial comparison; original registry record unchanged."
    }
  ],
  "rights": "Underlying source rights remain with their respective owners. No licence for the underlying papers or registry is granted by this export."
}